Gegenanzeigen · Neparvis
Neparvis 6 mg/6 mg granules in capsules for opening Neparvis 15 mg/16 mg granules in capsules for opening · Abschnitt 4.3 · PDF-Seite 24
HOS-138121 · Präparat HOS-098142
• Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. • Concomitant use with ACE inhibitors (see sections 4.4 and 4.5). Neparvis must not be administered until 36 hours after discontinuing ACE inhibitor therapy. • Known history of angioedema related to previous ACE inhibitor or ARB therapy (see section 4.4). • Hereditary or idiopathic angioedema (see section 4.4). • Concomitant use with aliskiren-containing medicinal products in patients with diabetes mellitus or in patients with renal impairment (eGFR <60 ml/min/1.73 m2) (see sections 4.4 and 4.5). • Severe hepatic impairment, biliary cirrhosis and cholestasis (see section 4.2). • Second and third trimesters of pregnancy (see section 4.6).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-13T16:33:00Z · SHA-256 08c9e21821039ca07b73a73e3ade3e3cdcfc16fa2da815f0f3e25e38fa083f2e · Passage 7a3d8c72f800c43823addc056f1b4c4dd7e4790bb0fa1bca03e14615f5fcb679 · Zeichen 0–786 im Abschnitt